Enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor, is superior to placebo in improving mucocutaneous symptoms of cutaneous and systemic lupus, according to data ...
FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback